Claims for Patent: 8,232,262

Summary for Patent: 8,232,262

Title:	Salts of isophosphoramide mustard and analogs thereof as anti-tumor Agents
Abstract:	The present disclosure relates to salts and compositions of isophosphoramide mustard and isophosphoramide mustard analogs. In one embodiment the salts can be represented by the formula ##STR00001## wherein A.sup.+ represents an ammonium species selected from the protonated (conjugate acid) or quaternary forms of aliphatic amines and aromatic amines, including basic amino acids, heterocyclic amines, substituted and unsubstituted pyridines, guanidines and amidines; and X and Y independently represent leaving groups. Also disclosed herein are methods for making such compounds and formulating pharmaceutical compositions thereof. Methods for administering the disclosed compounds to subjects, particularly to treat hyperproliferative disorders, also are disclosed.
Inventor(s):	Morgan; Lee Roy (New Orleans, LA)
Assignee:	DEKK-TEC, Inc. (New Orleans, LA)
Application Number:	11/666,215
Patent Claims:	1. A method for treating a subject having a hyperproliferative disorder, comprising administering to the subject a compound of the formula: ##STR00016## wherein A.sup.+ represents an ammonium species selected from quaternary ammonium, the conjugate acid of a basic amino acid, aliphatic ammonium, heterocyclic ammonium, aromatic ammonium, substituted and unsubstituted pyridinium, guanidinium, and amidinium; and X and Y independently represent leaving groups. 2. A method of claim 1, comprising administering from 10 mg/m.sup.2/day to 700 mg/m.sup.2/day of the compound to the subject. 3. A method of claim 1, comprising administering from 100 mg/m.sup.2/day to 500 mg/m.sup.2/day of the compound to the subject. 4. A method of claim 1, further comprising administering a second compound to the subject. 5. A method of claim 4, wherein the second compound is selected from the microtubule binding agents, DNA intercalators or cross-linkers, DNA synthesis inhibitors, DNA and/or RNA transcription inhibitors, enzyme inhibitors, gene regulators, enzymes, antibodies and angiogenesis inhibitors. 6. A method of claim 4, wherein the second compound is selected from paclitaxel, docetaxel, daunorubicin, cisplatin, carboplatin, oxaliplatin, colchicine, dolastatin 15, nocodazole podophyllotoxin, rhizoxin, vinblastine, vindesine, vinorelbine (navelbine), the epothilones, the mitomycins, bleomycin chlorambucil, carmustine, melphalan, mitoxantrone 5-fluoro-5'-deoxyuridine, camptothecin, topotecan, irinotecanetoposide, tenoposide, geldanamycin, methotrexate, adriamycin, actinomycin D, mifepristone, raloxifene, 5-azacytidine, 5-aza-2'-deoxycytidine, zebularine, tamoxifen, 4-hydroxytamoxifen, apigenin, rapamycin, angiostatin K1-3, L-asparaginase, staurosporine, genistein, fumagillin, endostatin, thalidomide and analogs thereof. 7. A method of claim 4, further comprising administering a third compound to the subject, wherein the third compound is selected from the microtubule binding agents, DNA intercalators or cross-linkers, DNA synthesis inhibitors, DNA and/or RNA transcription inhibitors, enzyme inhibitors, gene regulators, enzymes, antibodies and angiogenesis inhibitors. 8. A method of claim 1, wherein the hyperproliferative disorder comprises breast cancer, bladder cancer, bone cancer, cervical cancer, colon cancer, central nervous system cancer, esophageal cancer, gall bladder cancer, gastrointestinal cancer, head and neck cancer, Hodgkin's Disease, non-Hodgkin's lymphomas, laryngeal cancer, leukemia, lung cancer, melanoma, neuroblastoma, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, renal cancer, retinoblastoma, stomach cancer, testicular cancer or Wilms tumor. 9. A method of claim 1, wherein the hyperproliferative disorder comprises an adenocarcinoma, sarcoma, leukemia or lymphoma. 10. A method of claim 1, wherein the hyperproliferative disorder comprises a cutaneous tumor. 11. A method of claim 10, wherein the tumor is metastatic. 12. A method of claim 10, wherein the hyperproliferative disorder comprises melanoma, sarcoma, or both. 13. A method of claim 12, wherein the hyperproliferative disorder comprises melanoma. 14. A method of claim 1, wherein the hyperproliferative disorder comprises an ovarian, breast, lung, prostate or rectal cancer. 15. A method of claim 14, wherein the lung tumor is a non-small cell or small cell lung cancer tumor. 16. A method of claim 15, wherein the lung tumor is a non-small cell lung cancer tumor. 17. A method for producing a lyophilisate comprising contacting a compound of the formula: ##STR00017## wherein X and Y independently represent leaving groups, with at least one equivalent of an amine base selected from the basic amino acids, aliphatic amines, heterocyclic amines, aromatic amines, substituted and unsubstituted pyridines, guanidines, and amidines in the presence of water; and lyophilizing the result mixture, thereby forming the lyophilisate of an ammonium salt of compound (II). 18. A method of claim 17, wherein X and Y are chlorine. 19. A method of claim 17, wherein the amine base is lysine. 20. A lyophilisate produced by the method of claim 17. 21. A method of claim 1, wherein the compound has an intravenous LD.sub.50 in mice that is greater than the intravenous LD.sub.50 of isophosphoramide mustard. 22. A method of claim 1, wherein the compound has an intravenous LD.sub.10 in mice that is greater than the intravenous LD.sub.10 of isophosphoramide mustard. 23. A method of claim 1, wherein the compound has an intravenous LD.sub.50 in mice of from about 184 to about 265 mg/kg. 24. A method of claim 1, wherein the compound has an intravenous LD.sub.10 in mice of from about 65 to about 172 mg/kg. 25. A method of claim 1, wherein the compound has an intravenous LD.sub.50 in rates of from about 400 to about 570 mg/kg. 26. A stabilized isophosphoramide mustard salt, wherein the salt has a half-life at room temperature in the presence of water that is grater than a half-life of isophosphoramide mustard in the presence of water under the same conditions. 27. A lyophilisate of claim 20, wherein the compound is more stable than a lyophilized preparation of isophosphoramide mustard. 28. A method of claim 1, wherein the compound is more effective against CPA-resistant tumor growth than CPA, Ifos, or both. 29. A method of purifying a salt of a compound of the formula ##STR00018## wherein X and Y independently represent leaving groups, comprising filtering a solution of the compound through a sterile antimicrobial filter, whereby the purified compound undergoes less than 10% decomposition during filtration. 30. A method of claim 29, wherein the purified compound undergoes less than 5% decomposition during filtration. 31. A method of claim 30, wherein the purified compound undergoes less than 1% decomposition during filtration. 32. A method for treating a subject having a hyperproliferative disorder, comprising administering to the subject a composition produced by the method of claim 29. 33. A method of claim 17, wherein the amine base is tris(hydroxymethyl)methylamine. 34. The method of claim 1, wherein A.sup.+ represents an acyclic aliphatic ammonium that includes one or more substitutions with a hydroxy group. 35. The method of claim 34, wherein the acyclic aliphatic ammonium is tris(hydroxymethyl)methylamine. 36. The method of claim 1, wherein X and Y independently are selected from the halogens and the sulfonates. 37. The method of claim 36, wherein X and Y are each halogen. 38. The method of claim 37, wherein X and Y are each chlorine. 39. A method for treating a subject having a hyperproliferative disorder, comprising administering to the subject the lyophilisate of claim 17. 40. The method of claim 4, wherein the second compound is selected from microtubule binding agents, DNA intercalators or cross-linkers and enzyme inhibitors. 41. A method of claim 4, wherein the second compound is selected from carboplatin, etoposide, doxorubicin and docetaxel. 42. A method for treating abnormal or pathological proliferative activity of a cyclophosphamide (CPA) resistant cell in a subject in need thereof, comprising contacting the cell with a salt of isophosphoramide mustard (IPM) or a salt of an IPM analogue of the formula: ##STR00019## wherein X and Y independently represent halogens. 43. A method for treating abnormal or pathological proliferative activity of a cell in a subject in need thereof, comprising contacting the cell with a salt of isophosphoramide mustard (IPM) or a salt of an IPM analogue of the formula: ##STR00020## wherein X and Y independently represent halogens, in the presence of at least one additional therapeutic agent. 44. A method for inhibiting growth of, a CPA-resistant tumor in a subject in need thereof, comprising contacting the tumor with a salt of isophosphoramide mustard (IPM) or a salt of an IPM analogue of the formula: ##STR00021## wherein X and Y independently represent halogens. 45. A method for inhibiting growth of a tumor in a subject in need thereof, comprising contacting the tumor with a salt of isophosphoramide mustard (IPM) or a salt of an IPM analogue of the formula: ##STR00022## wherein X and Y independently represent halogens, and further comprising contacting the tumor with at least one additional therapeutic agent. 46. The method of claim 43 or 45, wherein the at least one additional therapeutic agent is selected from microtubule binding agents, DNA interealators or cross-linkers, and enzyme inhibitors. 47. The method of claim 43 or 45, wherein the at least one additional therapeutic agent is selected from carboplatin, etoposide, doxorubicin, and docetaxel.

Details for Patent 8,232,262

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2024-10-25